Amylyx Pharmaceuticals, Inc.
AMLXPharmaceutical Preparations · SIC 2834 · CIK 0001658551
Revenue FY2025
$0.0M
Net Income
$(145.0M)
EPS (Basic)
$-1.53
Net Margin
—
ROE
-47.4%
Total Equity
$305.0M
Shares Out
111M
Amylyx Pharmaceuticals, Inc. — Pharmaceutical Preparations. Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2021–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.
Revenue & Net Income (10Y)
Margin Trends
Investor Ownership · 3 funds in our universe
FundPosition Value% of AUMQoQ ChgWeight
Adage Capital Management
Adage Capital Management
$34.1M
0.0%
(46.6%)
OrbiMed Advisors
OrbiMed Advisors
$3.3M
0.0%
NEW
Alps Advisors
Alps Advisors
$2.0M
0.0%
+25.0%
Insider Transactions
Reading stored insider transactions…